Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 6/20 | 0.40 |
| ▸ | HTR6 | P50406 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4593379 | 0.84 | HSPB1 (0.39) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL306564 | 0.84 | MET (0.41) | HSPB1HTR6HTR2AMET | |
| SCHEMBL307788 | 0.82 | MET (0.44) | HSPB1HTR6ALDH1A1MAPTMAPK1 | |
| SCHEMBL307501 | 0.80 | MET (0.43) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL10254970 | 0.72 | HSPB1 (0.50) | HSPB1ALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL31333875 | 0.70 | HTR6 (0.53) | HTR6HTR2AALDH1A1KMT2AKHK | |
| SCHEMBL10036372 | 0.70 | HTR6 (0.53) | HTR6HTR2AALDH1A1KMT2AKHK | |
| SCHEMBL6410070 | 0.68 | HTR6 (0.53) | HTR6HTR2AALDH1A1KHK | |
| SCHEMBL8819038 | 0.68 | SIGMAR1 (0.41) | HTR6HTR2AALDH1A1MAPTGAA | |
| SCHEMBL10202679 | 0.67 | MET (0.41) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | HSPB1 2247/4885HTR6 1391/4885HTR2A 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.